NICE support Bayer’s and Novartis treatments for sight condition

NICE have issued updated guidelines for the treatment of wet age-related macular degeneration, by continuing to back use of both Bayer’s Eylea and Novartis’ Lucentis. According to the guidelines issued by NICE, the intravitreal anti-vascular endothelial growth factor (VEGF) treatment should be recommended for late AMD (wet active) for eyes with visual acuity within a

Continue Reading

Projects examines FDA approved drugs for Alzheimer’s leads to concerns over research

It has been quite a disappointing period recently for researching Alzheimer’s disease treatments in the last week, after Pfizer announced it would be shutting its neuroscience division and Axovant’s drug candidate flopped. This recent activity has led to serious fears over the development of potential treatments in the future, as companies become increasingly cautious over

Continue Reading

NICE publish final draft guidelines for GSK’s gene therapy, Strimvelis

NICE have now published final draft guidance approving GlaxoSmithKline’s gene therapy Strimvelis for an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome. Severe combined immunodeficiency due to adenosine deaminase deficiency, (ADA-SCID) is an inherited genetic condition affecting the body’s white blood cells, that renders the body’s immune system unable to function properly,

Continue Reading

Merry Christmas and a Happy New Year from Regulatory Professionals

Regulatory Professionals, part of the Clinical Professionals Group, held their annual Christmas Day, including a bake sale, secret Santa and wearing Christmas jumpers all to aid our corporate charity, Bloodwise. Bloodwise is a UK based charity that is dedicated to funding research into all blood cancers, including leukaemia, lymphoma and myeloma. Bloodwise also offers support

Continue Reading